Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 247 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pruritus Clear all
Active, not recruiting Phase 3 Interventional

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

NCT06455202
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
barzolvolimab, Matching placebo
Biological
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
63
States / cities
Cullman, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

NCT03816891
View directory record Official record
Conditions
Prurigo Nodularis, Pruritis
Interventions
Vixarelimab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis

NCT01891305
View directory record Official record
Conditions
Tinea Pedis
Interventions
VT-1161, placebo
Drug
Lead sponsor
Viamet
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • Miami, Florida • Miramar, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Jul 23, 2026, 11:13 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

NCT04325802
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Jul 23, 2026, 11:13 AM EDT
Not listed No phase listed Observational

An Observational Study of Pruritus Amongst Hemodialysis Patients

NCT00715260
View directory record Official record
Conditions
Pruritus, Kidney Failure, Chronic, Hemodialysis, Chronic Disease
Interventions
Not listed
Lead sponsor
Acologix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Augusta, Georgia • Metaire, Louisiana • Springfield, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2008 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

NCT03668613
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque-type Psoriasis
Interventions
secukinumab low dose, secukinumab high dose
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Fountain Valley, California • Jacksonville, Florida • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 2 Interventional Results available

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis

NCT02057718
View directory record Official record
Conditions
Progressive Familial Intrahepatic Cholestasis (PFIC)
Interventions
LUM001 (Maralixibat)
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
12 Months to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 4 Interventional

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis

NCT05265910
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
olopatadine hydrochloride ophthalmic solution 0.7%, loratadine 10 mg, Tears Naturale, Placebo
Drug
Lead sponsor
Andover Research Eye Institute
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Not applicable Interventional

Comparing Patient Satisfaction With Pataday or Bepreve

NCT01450176
View directory record Official record
Conditions
Eye Allergies
Interventions
Olopatadine hydrochloride 0.2%, Bepotastine besilate ophthalmic solution 1.5%
Drug
Lead sponsor
McCabe Vision Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Murfreesboro, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Jul 23, 2026, 11:13 AM EDT
Withdrawn Not applicable Interventional

Pain and Itch Reduction in Burn Scars Treated With Fractional CO2 Laser

NCT04364217
View directory record Official record
Conditions
Hypertrophic Scar, Burn Scar
Interventions
Luminis ultrapulse fractional ablative carbon dioxide laser
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 23, 2026, 11:13 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)

NCT04612725
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Benralizumab, Placebo and Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

NCT02143648
View directory record Official record
Conditions
Uremic Pruritus, Pruritus
Interventions
nalbuphine HCl ER tablets 60 mg BID, nalbuphine HCl ER tablets 120mg BID, Placebo tablets BID
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Jul 23, 2026, 11:13 AM EDT
Recruiting Phase 3 Interventional

Novel Strategies for Reducing Burn Scar Itch

NCT06801626
View directory record Official record
Conditions
Burn Scar, Itch Scarring, Wound
Interventions
Famotidine and 4% topical cromolyn sodium, Placebo
Combination Product · Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

NCT05936567
View directory record Official record
Conditions
Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria, Hives, Angioedema, Pruritis
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 1 Interventional

Treatment of Chronic Itch in Atopic Dermatitis (Eczema): Nerve Function

NCT02268448
View directory record Official record
Conditions
Cutaneous Nerves CNS Itch
Interventions
Clonidine, Naltrexone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jul 23, 2026, 11:13 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

NCT06736262
View directory record Official record
Conditions
Urticaria Chronic
Interventions
Briquilimab
Drug
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 23, 2026, 11:13 AM EDT
Completed No phase listed Observational

Study of Kids Itch Severity (SKIS)

NCT02672579
View directory record Official record
Conditions
Chronic Pruritus
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
4 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Jul 23, 2026, 11:13 AM EDT
Recruiting No phase listed Observational

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

NCT06627335
View directory record Official record
Conditions
Pregnancy Related, Atopic Dermatitis
Interventions
Ruxolitinib Cream, TCS
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
14 Years and older · Female only
Enrollment
5,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis

NCT01358240
View directory record Official record
Conditions
Tinea Pedis, Athlete's Foot
Interventions
Econazole Nitrate Foam 1%, Vehicle Foam, Econazole Nitrate Cream 1%, Placebo Cream
Drug · Other
Lead sponsor
AmDerma
Industry
Eligibility
12 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Fremont, California • Hockessin, Delaware • Boca Raton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 2 Interventional

Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus

NCT02229929
View directory record Official record
Conditions
Pruritus, Uremic Pruritus
Interventions
Part A: Placebo, Part A: CR845 0.5 mcg/kg, Part A: CR845 1.0 mcg/kg, Part A: CR845 2.5 mcg/kg, Part B: Placebo, Part B: CR845 1.0 mcg/kg
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Pine Bluff, Arkansas • Chula Vista, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Jul 23, 2026, 11:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurobiology of the Scalp in Seborrheic Dermatitis

NCT02349854
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Biopsy
Procedure
Lead sponsor
Boston University
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Jul 23, 2026, 11:13 AM EDT
Active, not recruiting Phase 3 Interventional

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

NCT05677451
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 (blinded), placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
11
States / cities
Bakersfield, California • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 11:13 AM EDT
Terminated Early Phase 1 Interventional

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

NCT03185169
View directory record Official record
Conditions
Genitourinary Abnormality, Breast Cancer Female, Vaginal Abnormality, Urinary Tract Infections, Dyspareunia, Dysuria
Interventions
Replens and coconut oil
Combination Product
Lead sponsor
Alta Bates Summit Medical Center
Other
Eligibility
Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 3 Interventional

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

NCT00814073
View directory record Official record
Conditions
Indolent Systemic Mastocytosis
Interventions
Masitinib, Placebo, Best Supportive Care
Drug · Other
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Sacramento, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Jul 23, 2026, 11:13 AM EDT